United Kingdom

At GSK, we unite science, technology and talent to get ahead of disease together.

We prevent and treat disease with vaccines, specialty and general medicines investing in four core therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology. 

Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.

GSKH team member sitting at the desk

Currently, we invest around £1bn in research and development (R&D) in the UK annually with our global R&D hub at Stevenage continuing to be at the heart of the development of our pipeline of vital medicines, with a focus on the immune system, genetics, and advanced technologies.

Our culture powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. We are recognised in the Stonewall LGBT+ rights group as a top global employer and ranked in the Times Top 50 employers for women in the UK.

We also support our global and local communities. £1.7m has been raised by UK employees for Save the Children so far, with 100% of these funds being used to help provide UK families living on low incomes with essential household items, learning resources, and support that gives parents the skills, confidence and tools to help their children thrive.

Members of the public in the UK can obtain information about our products and areas of therapy by visiting our

GSK UK product website

Our locations in the UK

Contact details

GSK HQ
79 New Oxford Street
London
United Kingdom
WC1A 1DG


UK Corporate 
Tel: +44 (0)20 8047 5000

UK Commercial 
Tel: +44 (0)20 8990 9000

Back to top

Prescription medicines/customer support team
Email: customercontactuk@gsk.com

UK medical and safety information
Tel: 0800 221 441

Back to top

For general media enquiries visit Global media contacts

Back to top

We routinely monitor the safety of all our medicines and all adverse events should be reported to us and the Medicines and Healthcare products Regulatory Agency via their yellow card scheme. To report an adverse event, use our online Patient safety reporting form  or email: uksafety@gsk.com  or tel: 0800 221 441

 

Back to top

Use the UK HR main number to contact the right team for information regarding benefits and employment related questions: 

Email: UKIRL.ServiceHR@gsk.com
Tel: +44 (0)20 7660 6942

 

Back to top

Healthcare professionals

Healthcare professionals (HCPs) in the UK can get information about our products and therapy areas by visiting GSKPro

As a healthcare company we regularly work with HCPs. From collaborating on clinical trials to providing high quality, balanced information about our medicines and vaccines, in all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first. 


In line with EFPIA Disclosure Code, disclosure information in the UK is published annually (covering the previous year) through the Association of the British Pharmaceutical Industry (ABPI) Disclosure UK website. You can find more information on our disclosure of payments here.

Back to top

UK patients, journalists and members of public

In line with ABPI Code, we disclose payments for certain contracted services made to UK patients, journalists and members of the public, on an aggregate basis.

Partnerships

Despite having some of the best people and research facilities, experience has shown us that we can achieve even more through strong partnerships.

These can be with the NHS, other companies, non-profit organisations and the academic world. In fact, it’s a key element in our business strategy, which helps us develop innovative new medicines and vaccines but also helps improve access to treatments and patient care

Joint working

We are actively involved in a wide number of joint working projects with the NHS throughout the UK. By working together we aim to improve the management of different conditions, introduce greater efficiency introduce greater efficiency and to achieve our ambition to unite science, technology and talent to get ahead of disease together.

The projects outlined below were undertaken over the last five years and, over this period, codes, regulations and laws governing the areas covered by the studies may have changed. When reading the documents please be assured that all projects followed the particular standards in force at the time even though these may have subsequently changed.

All of the featured case studies are intended to give an overview of the individual project including its background, the potential benefits for the patient, the NHS, GSK and any other stakeholders.

 


 

Back to top

Grants and donations

We recognise a responsibility to support activities in our medical community, whether related to medical education where there is patient need and common scientific interest, professional societies’ initiatives, or assisting healthcare organisations and projects that promote other healthcare goals. In all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first. 

GSK UK’s Grants and Donations Committee uses the following criteria when assessing applications from Healthcare Organisations and Patient Advocacy Groups:

  1. The grant or donation must be used for an activity with a valid and legitimate purpose that enhances patient care, or benefits the NHS and maintains patient care. Programmes currently within scope for approval include:
  • Patient Advocacy Group initiated Programmes and Core Funding
  • Grants to organisations that support healthcare professionals and related staff to attend Scientific Congresses with decision-making independent of GSK
  •  Public policy and advocacy programs and initiatives, including legal reform and government relations
  1. The activity must be in a GSK disease area of strategic priority: Respiratory, Oncology, Specialty and COVID-19, Vaccines.
  2. Funding must be proportional to the activity and not excessive.
  3. Applications must be from a legitimate, reputable organisation that has the capability and licences to conduct the activity.
  4. The grant must be made in a manner that does not affect the independence of the recipient.
  5. A grant will only extend beyond one year under exceptional circumstances.
  6. A grant will not be given to an individual or be used for personal use.
  7. A grant cannot provide more than 25% of total funding received by a single recipient through GSK grants, except for rare disease or start-up patient groups, which can receive up to 50% of the total funding. Any exception requires additional approval and shall not exceed 50% in any case.

Please return your completed request form to gsk.grant-request@gsk.com. We will review qualifying grant requests and may reach out for additional information.

Carbon reduction plan

In accordance with UK Cabinet Office standards, the attachment below is GSK’s Carbon Reduction Plan completed in accordance with PPN 06/21 and associated guidance and reporting standards for Carbon Reduction Plans.